Ropivacaine-d₇

Name: Ropivacaine-d 7
Brand: MedChemExpress
SKU: HY-B0563S1
Rating: 4.5 (1 reviews)

Cat. No.: HY-B0563S1 Purity: 99.38%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].

For research use only. We do not sell to patients.

Ropivacaine-d<sub>7</sub> Chemical Structure

Ropivacaine-d₇ Chemical Structure

CAS No. : 684647-62-9

Size	Price	Stock	Quantity
1 mg	USD 220	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 990	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 1740	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Ropivacaine-d₇:

Ropivacaine In-stock
Ropivacaine hydrochloride monohydrate In-stock
Ropivacaine hydrochloride In-stock
Ropivacaine-d₇ hydrochloride In-stock
Ropivacaine mesylate In-stock
(Rac)-Ropivacaine-d₇ Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

281.44

Formula

C₁₇H₁₉D₇N₂O

CAS No.

684647-62-9

Appearance

Solid

Color

White to off-white

SMILES

CC(C=CC=C1C)=C1NC([C@H]2N(CCCC2)C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (355.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5532 mL	17.7658 mL	35.5316 mL
5 mM	0.7106 mL	3.5532 mL	7.1063 mL
10 mM	0.3553 mL	1.7766 mL	3.5532 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.38%

Select Batch:

Data Sheet (280 KB) SDS (251 KB)

COA (259 KB) HNMR (137 KB) RP-HPLC (306 KB) LCMS (106 KB)

Handling Instructions (2659 KB)

References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]

[2]. Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65(18):2675-717. [Content Brief]

[3]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321. [Content Brief]

[4]. Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth [Content Brief]

[5]. Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5532 mL	17.7658 mL	35.5316 mL	88.8289 mL
	5 mM	0.7106 mL	3.5532 mL	7.1063 mL	17.7658 mL
	10 mM	0.3553 mL	1.7766 mL	3.5532 mL	8.8829 mL
	15 mM	0.2369 mL	1.1844 mL	2.3688 mL	5.9219 mL
	20 mM	0.1777 mL	0.8883 mL	1.7766 mL	4.4414 mL
	25 mM	0.1421 mL	0.7106 mL	1.4213 mL	3.5532 mL
	30 mM	0.1184 mL	0.5922 mL	1.1844 mL	2.9610 mL
	40 mM	0.0888 mL	0.4441 mL	0.8883 mL	2.2207 mL
	50 mM	0.0711 mL	0.3553 mL	0.7106 mL	1.7766 mL
	60 mM	0.0592 mL	0.2961 mL	0.5922 mL	1.4805 mL
	80 mM	0.0444 mL	0.2221 mL	0.4441 mL	1.1104 mL
	100 mM	0.0355 mL	0.1777 mL	0.3553 mL	0.8883 mL